CBU
LABU icon

CIBC Bancorp USA’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

CIBC Bancorp USA’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$623K Buy
+3,750
New +$615K ﹤0.01% 1164

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CIBC Bancorp USA's LABU Position: Q1 2026 in Review

CIBC Bancorp USA opened a new position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2026: 3,750 shares worth $623K. The stake represents ﹤0.01% of the portfolio and ranks #1164 among its holdings.

33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • CIBC Bancorp USA held 3,750 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $623K as of Q1 2026.
  • Direxion Daily S&P Biotech Bull 3X ETF was a new CIBC Bancorp USA position in Q1 2026.
  • Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q1 2026, its #1164 holding.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on CIBC Bancorp USA's 13F filing for Q1 2026, filed 12 May 2026.